42
nanotimes
Companies Facts
specific data analysis pipelines for Pipeline Pilot will be offered as the preferred and supported solution for secondary and higher level data analysis for the Oxford Nanopore DNA sequencing system at the time of its commercial release.
http://www.nanoporetech.com
P
harmacelsus GmbH, Germany, announced its participation in the 4 year multi-national
research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for re- spiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germa- ny, Bulgaria, Lithuania, and the Netherlands. Pharmacelsus will contribute its in vitro ADMET and in vivo pharmacokinetics expertise through sophi- sticated safety tests and by screening several drug candidates for beneficial pharmacological properties. The project started in October 2010 and runs for 4 years with almost EUR6 million in funding provided by the EU. The FLUCURE project aims at developing innovative, first-in-class therapeutics against influenza by targeting its replication machinery. Small mole- cule inhibitors will be designed that interfere with virus-specific protein-protein interactions ultimately avoiding viral replication and spread. A consortium of 10 European partners will bring their expertise together to deliver several drug candidates suitable for clinical development.
http://www.pharmacelsus.de
P
hononic Devices closed a $10 million series B investment from Venrock and Oak Investment Partners. Phononic Devices is a private research and
development company that innovates high perfor- mance, environmentally friendly and commercially transforming thermoelectric materials, devices and fully integrated thermal management systems.
http://www.phononicdevices.com
P
I introduces a new, more affordable series of Fast Piezo Focusing devices at the 2011 SPIE BIOS
(Biomedical Optics) meeting in San Francisco, CA. The new PIFOC®
system packages are designed to
improve results in fast focussing & lens positioning as well in deconvolution / 3D imaging, and reduce costs at the same time. The PIFOC®
piezo objective
scanner system packages consist of closed-loop pie- zomechanic objective positioners and custom-tuned compact ditigal servo controller / driver units. This combination provides higher performance at reduced costs. The integrated, frictionless and high-stiffness piezo flexure drive ensures fast response and short settling times, as well as exceptional guiding accu- racy. The settling time of less than 10ms increases throughput and allows for rapid Z-stack acquisition.
http://www.physikinstrumente.com/en/literature_RFQ/ index.php
P the UNIarray®
rotagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, will be using Platform to help discover biomarkers
in relapsing remitting multiple sclerosis for Biogen Idec, Inc. Under the terms of the agreement, Pro- tagen will apply its UNIarray®
technology platform
and expertise in autoantibody research to support retrospective analysis of samples from a Biogen Idec clinical trial for the purpose of finding predictive and response biomarkers associated with multiple sclero- sis (MS) therapy.
http://www.protagen.de
11-02/03 :: February / March 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95